Lerdelimumab

Lerdelimumab (also known as CAT-152) is a human monoclonal antibody that was designed for the treatment of ocular surface diseases. It was developed by Cambridge Antibody Technology and was later licensed to Genzyme.

History[edit | edit source]

Lerdelimumab was developed by Cambridge Antibody Technology, a biotechnology company based in the United Kingdom. The company was later acquired by AstraZeneca, a multinational pharmaceutical and biopharmaceutical company. Lerdelimumab was licensed to Genzyme, a biotechnology company based in the United States, for further development and commercialization.

Mechanism of Action[edit | edit source]

Lerdelimumab is a human monoclonal antibody that targets TGF-beta 2, a cytokine that plays a crucial role in the development of fibrosis and scarring. By blocking the action of TGF-beta 2, Lerdelimumab can potentially prevent or reduce scarring and fibrosis in ocular surface diseases.

Clinical Trials[edit | edit source]

Lerdelimumab has undergone several clinical trials to evaluate its safety and efficacy in treating ocular surface diseases. However, the results of these trials have not been conclusive, and the development of Lerdelimumab has been discontinued.

Potential Applications[edit | edit source]

Despite the discontinuation of its development, Lerdelimumab has potential applications in the treatment of other diseases characterized by fibrosis and scarring, such as kidney disease, liver disease, and pulmonary fibrosis.